ArticleCell biology international2025
Synergistic Reduction of Breast Cancer Cell Viability and Aggressiveness Through Dual Inhibition of APE1 Redox Function and STAT3 Signaling.
Article in Cell biology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Aggressiveness and resistance to treatments are significant problems in cancer management. In this scenario, searching for new pharmacological targets for therapies is essential. The APE1 redox domain coactivates transcription factors that favor cancer malignancy. One of APE1's targets, STAT3, coordinates the transcription of genes involved in cancer hallmarks. However, the association between APE1 and STAT3 in the context of breast cancer cell survival and aggressiveness has not been previously characterized. Therefore, we investigated the role of the redox function of APE1 and STAT3 inhibitors in cell viability, proliferation, migration, invasion, and cell death. In addition, we verified the association between APE1 and STAT3 in breast cancer patient samples from TCGA and their relationship with proliferation and metastasis. Our results suggest that combined treatment with APE1 and STAT3 inhibitors can further synergistically reduce cell viability, proliferation, migration, and invasion, compared to treatment with inhibitors alone. Moreover, the APE1 and STAT3 activity levels positively correlated with proliferation and metastasis gene signatures. Thus, we suggest the APE1 redox domain and STAT3 as promising targets for new therapy strategies against breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.